Clinical Trial

QL1706 Plus Chemotherapy as Neoadjuvant Therapy in Triple-Negative Breast Cancer

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This is a single-center, single-arm, prospective study enrolling 30 patients with stage II-III triple-negative breast cancer. The neoadjuvant regimen consists of QL1706 combined with carboplatin plus albumin-bound paclitaxel (21-day cycles for 4 cycles) followed by QL1706 combined with doxorubicin/epirubicin plus cyclophosphamide (21-day cycles for 4 cycles). The treatment observation period is 1 year, and the primary endpoint is the pathological complete response rate.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2026-01-08.
Status change: Not Yet Recruiting → Recruiting 2026-02-26
Trial Details
NCT Number NCT07342283
Lead Sponsor Affiliated Hospital of Nantong University
Conditions Triple Negative Breast Cancer (TNBC)
Enrollment 30 participants
Start Date 2026-02-25
Primary Completion 2027-12-25 (estimated)
Study Completion 2028-12-25 (estimated)
Updated on ClinicalTrials.gov 2026-03-02